"The World Health Organization has issued new recommendations to help countries reach the 8.1 million people living with HIV that are yet to be diagnosed, and that are therefore not able to obtain lifesaving therapy,"-based on WHO press release on November 27, 2019.
From the end of 2019, 37.8 million people were living with HIV worldwide. If you want to explore about elisa data interpretation visit https://www.bosterbio.com/elisa-data-analysis-instructions
One of them, 79 percent have been diagnosed, 63 percent are under the HIV phase of 54 percent has decreased, lowering the bedspread of HIV risk throughout sustained therapy.
A horrifying figure indicates that around 2/3 of those people infected with HIV are living in the African region where other epidemics such as Ebola, plague, dengue fever, malaria, and so forth are prevalent as well.
"The human immunodeficiency virus is evolving as new medication grow, and we have to find a system to detect it quickly," said the head of a life science company that has been dedicated to facilitating global medical researchers and medicine manufacturers in the business of research utilized HIV antibodies, which are well developed and thoroughly standardized to meet with each demand.
In line with the different detection goals, HIV detection reagents can be roughly divided into antibody/antigen detection reagents, nucleic acid detection reagents and HIV genotype drug resistance detection reagents.
Which could also be categorized as human immunodeficiency virus antibody rapid detection reagents, self-test reagents, antibody screening reagents, antibody diagnostic reagents, HIV antibody confirmation reagents, etc.
According to different characteristics, uses, and performances. One of them, the antibody/antigen reagents are gaining more and more attention due to their flash response in about 20 minutes.